CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.210
+0.170 (8.34%)
At close: Nov 20, 2024, 4:00 PM
2.090
-0.120 (-5.44%)
After-hours: Nov 20, 2024, 7:04 PM EST
CytoMed Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for GDTC stock has a target of 5.00, which predicts an increase of 126.22% from the current stock price of 2.21.
Analyst Consensus: Buy
* Price targets were last updated on Oct 10, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for GDTC is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +126.22% | Oct 10, 2024 |
Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +126.22% | Jun 11, 2024 |
Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +126.22% | Dec 4, 2023 |
Benchmark | Benchmark | Buy Initiates $5 | Buy | Initiates | $5 | +126.22% | Jul 21, 2023 |
Financial Forecast
Revenue This Year
582.42K
from 507.74K
Increased by 14.71%
Revenue Next Year
530.40K
from 582.42K
Decreased by -8.93%
EPS This Year
-0.15
from -0.39
EPS Next Year
-0.17
from -0.15
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 599,550 | 546,000 |
Avg | 582,420 | 530,400 |
Low | 559,580 | 509,600 |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | 18.1% | -6.3% |
Avg | 14.7% | -8.9% |
Low | 10.2% | -12.5% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -0.16 | -0.18 |
Avg | -0.15 | -0.17 |
Low | -0.15 | -0.17 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.